BergenBio Fundamentale Forhold (BGBIO)

Ekornet · juni 26, 2020, 7:30am

At det dupper litt nå viser vel at det er mye Covid-19 priset inn i aksjen p.d.d. Så frem til det avklares er det vanskelig å se at onkologien skal prises “riktig”. AXL positive responderte på behandlingen, Bgbio er langt fra opphausset spør du meg ihvertfall.

Martins · juni 26, 2020, 7:42am

Ja, seff. Det jeg lurte på var om 25% ORR var veldig bra her, da det ble nevnt at alt over 16% som var det man forventet før skulle være veldig bra.

arcone · juni 26, 2020, 8:00am

Er det vi ser i dag grunnet at det pågår en emisjon? At man håper å få overtegnet?
Det kan tenkes at etter 3 juli når man ikke har fått de overtegnede aksjene man ønsker går ut å kjøper dem direkte

laplagam · juni 26, 2020, 8:33am

Ryddet litt. Bruk småprat for diskusjon rundt kurs osv

Martins · juni 29, 2020, 10:52am

Deler Trinity Delta sin analyse av caset fra i dag 29. juni her så den er lett å finne senere.

Tekspert · juli 1, 2020, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@vcp (1144 likes)

@larsmkn (864 likes)

@Mykle (477 likes)

Resten av topp 10:

@ezPappi (374 likes)
@Ekornet (346 likes)
@Flottesen (341 likes)
@Savepig (339 likes)
@Magnus1 (315 likes)
@Timm (294 likes)
@Evilfreud (259 likes)

Gratulerer!

prump · juli 1, 2020, 2:47pm

https://newsweb.oslobors.no/message/509101

vcp · juli 1, 2020, 2:55pm

penger på gaten

Timm · juli 1, 2020, 3:18pm

Meteva kjøper nye 130,985 aksjer, og dette er som sikkert alle vet Trond Moen.

Hans pengeplasseringer virker lite tilfeldige. I tillegg til Meteva har han en stiftelse som i 2019 støttet bergensforskningen med 230 millioner, og benyttet seg da av 67 uavhengige eksperter :

Martins · juli 1, 2020, 3:35pm

Siden Covid-19 effekten ga BergenBio en 500M emisjon på 37.5kr/aksje tror jeg alle både nye og gamle bør være glade for at det skjedde. Oppmerksomhet rundt bemcentinib er også positivt for alle, om det er rundt Covid eller kreft. Funnene som gjøres i kreftstudiene og covidstudiet kan også gi data som støtter opp om hverandre, så alt i alt mer enn en bonus allerede i mine øyne. Deilig med et selskap som har klare planer og pengene til å få dem utført.

eiken · juli 1, 2020, 5:14pm

Siste gang han kjøpte 4 dobblet kursen seg innen kort tid =)

Ekornet · juli 3, 2020, 1:09pm

Bergenbio og AML:

Jeg og andre har skrevet mye om våre forventninger til Bemcentinib og AML. Har sett nærmere på potensielle konkurrenter. Gilteritinib er en FTL3 og AXL inhibitor, altså ikke selektiv AXL hemmer, som har fått godkjenning av FDA og EMA for en sub-populasjon av AML pasienter med en mutasjon for FTL3 i en residiv-setting. Denne medisinen er i flere kliniske studier og jeg må derfor bare beklage at jeg tidligere i våres skrev at det kun er Bergenbio som har gående studie på AXL-hemming og AML!

Det fine for oss er at Bergenbio sin Fasttrack går på hele pasientpopulasjonen med AML, som ofte er eldre pasienter uten andre behandlingstilbud og dermed i kategorien “high unmet need”, som kan gi raskere FDA godkjenning.

Et annet positivt aspekt ved dette er at studiene på Gilteritinib viser god effekt og vi vil kunne forvente oss at “våre” resultater på ASH i år følger i samme løype! Gilteritinib har vært plaget av endel bivirkninger, såpass mange at de har det over hele forsiden på nettsiden. Dette kan være betinget i at den ikke er selektiv i dens AXL hemming. @larsmkn har skrevet såvidt om dette tidligere om jeg ikke husker helt feil? For detaljer om bivirkninger: https://xospata.com/possible-side-effects Vi kan trygt si at Bemcentinib har bedre safety-profile!

Så for å summere: Bemcentinib er selektiv og har bedre safety-profil, pga gode resultater så langt og effekt av Gilteritinib så vil jeg ihvertfall forvente svært gode resutlater på ASH iår, og gruppen pasienter den er ment for går under “High unmet need” kategorien og derav Fasttrack hos FDA. God stemning. Igjen beklager mitt tidligere utsagn om at det var kun Bemcentinib som ble prøvd ut på AML, i sub-populasjonen med FTL3 mutasjon så foreligger det altså et annet medikament.

Og husk at det er Bemcentinib som er prøvd ut på det aller fleste pre-kliniske og investigator drevne kliniske studiene verden over, som sitert inn tidligere her på fundamental-tråden, som sammen med ACCORD studien etter mitt syn viser at det er Bemcentinib som ligger helt fremst blant AXL-hemmere og denne våren har befestet sin posisjon som sådan.

TekBot · juli 3, 2020, 1:26pm

BerGenBio ASA: Primary Insider notification

TekBot · juli 3, 2020, 1:27pm

BerGenBio ASA: Last day of subscription period in the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE
SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG
SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR
…

Vis børsmeldingen

JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT
THE END OF THE PRESS RELEASE

Bergen, Norway, 3 July 2020: Reference is made to the stock exchange
announcement from BerGenBio ASA (the “Company”) dated 19 June 2020 relating to
the subsequent offering and listing of up to 1,500,000 new shares, each with a
nominal value of NOK 0.10 (the Offer Shares") at a subscription price of NOK
37.50 per Offer Share (the Subscription Price") to be carried out by the Company
(the “Subsequent Offering”).

The subscription period for the Subsequent Offering will expire today, 3 July
2020, at 16:30 hours (CET). Correctly completed subscription forms must be
received by one of the subscription offices, or, in the case of online
subscriptions, be registered, within this deadline.

Please note that subscription rights that are not used to subscribe for Offer
Shares within the deadline will have no value and will lapse without
compensation to the holder.

For more information regarding the Subsequent Offering, please refer to the
prospectus from the Company dated 19 June 2020 (the “Prospectus”). The
Prospectus, including the subscription form, is, subject to applicable law,
available at https://www.bergenbio.com/prospectus/

Also, printed copies of the prospectus may be obtained at the offices of
BerGenBio ASA, Jonas Lies vei 91, 5009 Bergen, Norway or by contacting the
Managers (defined below).

Arctic Securities AS, Carnegie AS and DNB Markets, a part of DNB Bank ASA
(together the “Managers”) are acting as Joint Bookrunners and Managers for the
Subsequent Offering.

Advokatfirmaet Thommessen AS is acting as the Company’s legal adviser for the
Subsequent Offering.

END -

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
[email protected]
+47 917 86 513

IMPORTANT INFORMATION -

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful prior to registration,
exemption from registration or qualification under the securities laws of any
jurisdiction.

This communication may not be published, distributed or transmitted in or into
the United States, Canada, Australia, the Hong Kong Special Administrative
Region of the People’s Republic of China, South Africa or Japan and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States of America or to U.S. persons (as defined in the U.S.
Securities Act of 1933, as amended (the “Securities Act”)) or to publications
with a general circulation in the United States of America. This document is not
an offer for sale of securities in the United States. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under
Securities Act. BerGenBio does not intend to register any part of the offering
in the United States. There will be no public offering of the securities in the
United States of America.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”) or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as “relevant persons”). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act
or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to
this communication in any member state of the European Economic Area (each an
“EEA Member State”) that has implemented Directive 2003/71/EC (together with the
2010 PD Amending Directive 2010/73/EU, including any applicable implementing
measures in any Member State, the “Prospectus Directive”) is only addressed to
qualified investors in that Member State within the meaning of the Prospectus
Directive. This announcement is not a prospectus within the meaning of the
Prospectus Directive, as implemented in each member State of the European
Economic Area. With respect to the EEA Member States, no action has been
undertaken or will be undertaken to make an offer to the public of the
securities referred to herein requiring a publication of a prospectus in any
Member State. As a result, the securities of the Company may not and will not be
offered in any Member State except in accordance with the exemptions set forth
in Article 3 of the Prospectus Directive.

Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g.
statements including terms like “believe”, “assume”, “expect”, “forecast”,
“project”, “may”, “could”, “might”, “will” or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of BerGenBio and those
explicitly or implicitly presumed in these statements. Against the background of
these uncertainties, readers should not rely on forward-looking statements.
BerGenBio assumes no responsibility to update forward -looking statements or to
adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · juli 3, 2020, 6:58pm

BerGenBio ASA: Results of the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE
SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG
SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR
…

Vis børsmeldingen

JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT
THE END OF THE PRESS RELEASE

Bergen, Norway, 3 July 2020: Reference is made to the stock exchange
announcement from BerGenBio ASA (the “Company”) dated 19 June 2020 relating to
the subsequent offering and listing of up to 1,500,000 new shares, each with a
nominal value of NOK 0.10 (the Offer Shares") at a subscription price of NOK
37.50 per Offer Share (the Subscription Price") carried out by the Company (the
“Subsequent Offering”).

The subscription period for the Subsequent Offering expired today, 3 July 2020,
at 16:30 hours (CET). At the expiry of the subscription period the Company has
received subscriptions for 534,178 Offer Shares from eligible shareholders in
the Subsequent Offering.

The allocation of the Offer Shares will be resolved in accordance with the
allocation criteria set out in the prospectus dated 19 June 2020. The final
results of the Subsequent Offering will be published shortly thereafter, and
letters regarding allocation of Offer Shares and the corresponding subscription
amount to be paid by each eligible shareholder who has subscribed for Offer
Shares in the Subsequent Offering, will be distributed during the course of 6
July 2020.

Arctic Securities AS, Carnegie AS and DNB Markets, a part of DNB Bank ASA are
acting as Joint Bookrunners and Managers for the Subsequent Offering.

Advokatfirmaet Thommessen AS is acting as the Company’s legal adviser for the
Subsequent Offering.

END -

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
[email protected]
+47 917 86 513

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

IMPORTANT INFORMATION -

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful prior to registration,
exemption from registration or qualification under the securities laws of any
jurisdiction.

This communication may not be published, distributed or transmitted in or into
the United States, Canada, Australia, the Hong Kong Special Administrative
Region of the People’s Republic of China, South Africa or Japan and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States of America or to U.S. persons (as defined in the U.S.
Securities Act of 1933, as amended (the “Securities Act”)) or to publications
with a general circulation in the United States of America. This document is not
an offer for sale of securities in the United States. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under
Securities Act. BerGenBio does not intend to register any part of the offering
in the United States. There will be no public offering of the securities in the
United States of America.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”) or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as “relevant persons”). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act
or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to
this communication in any member state of the European Economic Area (each an
“EEA Member State”) that has implemented Directive 2003/71/EC (together with the
2010 PD Amending Directive 2010/73/EU, including any applicable implementing
measures in any Member State, the “Prospectus Directive”) is only addressed to
qualified investors in that Member State within the meaning of the Prospectus
Directive. This announcement is not a prospectus within the meaning of the
Prospectus Directive, as implemented in each member State of the European
Economic Area. With respect to the EEA Member States, no action has been
undertaken or will be undertaken to make an offer to the public of the
securities referred to herein requiring a publication of a prospectus in any
Member State. As a result, the securities of the Company may not and will not be
offered in any Member State except in accordance with the exemptions set forth
in Article 3 of the Prospectus Directive.

Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g.
statements including terms like “believe”, “assume”, “expect”, “forecast”,
“project”, “may”, “could”, “might”, “will” or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of BerGenBio and those
explicitly or implicitly presumed in these statements. Against the background of
these uncertainties, readers should not rely on forward-looking statements.
BerGenBio assumes no responsibility to update forward -looking statements or to
adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

vcp · juli 3, 2020, 7:00pm

En tredjedel der altså. Ikke verst med tanke på hvor lavt den gikk denne uken.

Rodjer · juli 3, 2020, 7:19pm

Mohn tar resterende:grinning:

vcp · juli 3, 2020, 7:24pm

Hadde han kunnet så hadde han trolig det.

Rodjer · juli 3, 2020, 7:25pm

Sikker på at han ikke kan?

larslars · juli 3, 2020, 8:32pm

Se opprinnelig melding om rep.emi:

TekBot:

Shareholders in the Company as of 4 May 2020 that have been registered as such
in the Norwegian Central Security Depository (VPS) as of 6 May 2020 (the “Record
Date”), and who were not allocated shares in the private placement announced by
the Company on 4 May 2020 and who are not resident in a jurisdiction where such
offering would be unlawful, or for jurisdictions other than Norway, would
require any filing, registration or similar action, and have an existing
shareholding below a threshold of 150,000 shares in the Company (the “Eligible
Shareholders”), will be granted non-transferable subscription rights (the
“Subscription Rights”) that, subject to applicable law, provide preferential
rights to subscribe for, and be allocated, Offer Shares at the Subscription
Price.